Company Profiles

driven by the PitchBook Platform

Crititech

Description

Developer of fine-particle compounds. The company is a drug-development business that hat utilizes its proprietary Super Critical CO2 Technology to develop and manufacture unique and differentiated drugs and medical devices for the human and animal health markets. The company specializes in optimizing delivery of challenging drug substances - potent molecules, poorly soluble compounds and biomolecules.By combining its Super Critical CO2 Technology with its ability to simplify formulations, is working to expand drug delivery options for oral, injectable, and inhaled drugs, as well as implantable devices.

1997

Founded

PRIVATE

Status

11-50

Employees

Conv. Debt

Latest Deal Type

$1.05M

Latest Deal Amount

$5.9M

Total Amount Raised

Description

Developer of fine-particle compounds. The company is a drug-development business that hat utilizes its proprietary Super Critical CO2 Technology to develop and manufacture unique and differentiated drugs and medical devices for the human and animal health markets. The company specializes in optimizing delivery of challenging drug substances - potent molecules, poorly soluble compounds and biomolecules.By combining its Super Critical CO2 Technology with its ability to simplify formulations, is working to expand drug delivery options for oral, injectable, and inhaled drugs, as well as implantable devices.

Website:

www.crititech.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Delivery

Primary Office

Post Box 442280 Lawrence, KS 66044United States +1 (785) 841-7120
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Crititech's full profile, request a free trial.

Crititech Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Crititech Investors (6)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
KTEC HoldingsCorporationMinority000 0000000 0000
National Institutes of HealthGovernment000 0000000 0000
Precede FundVenture CapitalMinority000 0000000 0000
SeedStep AngelsAngel GroupMinority000 0000000 0000
The TAC GroupCorporationMinority000 0000000 0000
KTEC Holdings Corporation
National Institutes of Health Government
Precede Fund Venture Capital
SeedStep Angels Angel Group
The TAC Group Corporation

Crititech Executive Team (8)

NameTitleBoard
Seat
Contact
Info
Sam CampbellPresident, Chief Strategy Officer & Chairman
Matthew McClorey JDPresident & Board Member
Jeffrey MorrisonChief Financial Officer
Michael Baltezor Ph.DChief Scientific Officer
Mike CampbellDirector of Facilities
Sam Campbell President, Chief Strategy Officer & Chairman
Matthew McClorey JD President & Board Member
Jeffrey Morrison Chief Financial Officer
Michael Baltezor Ph.D Chief Scientific Officer
Mike Campbell Director of Facilities

Crititech Board Members (7)

NameRepresentingRoleSinceContact
Info
Bala SubramaniamCrititechCo-Founder & Board Member000 0000
Francois SauerSelfBoard Member000 0000
Joseph Fix Ph.DSelfBoard Member000 0000
Matthew McClorey JDCrititechPresident & Board Member000 0000
Michele WeigandSelfBoard Member000 0000
Bala Subramaniam Co-Founder & Board Member Crititech
Francois Sauer Board Member Self
Joseph Fix Ph.D Board Member Self
Matthew McClorey JD President & Board Member Crititech
Michele Weigand Board Member Self
Request full access to PitchBook